Compare IQ & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | CTMX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.3M | 716.9M |
| IPO Year | 2017 | 2015 |
| Metric | IQ | CTMX |
|---|---|---|
| Price | $1.01 | $2.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $2.91 | ★ $12.10 |
| AVG Volume (30 Days) | ★ 9.0M | 3.6M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $3.54 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.98 |
| 52 Week High | $2.72 | $8.21 |
| Indicator | IQ | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 33.01 |
| Support Level | $0.99 | N/A |
| Resistance Level | $1.23 | $3.93 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 49.98 | 6.97 |
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.